Health & Biotech
Cannabis play Bod just raised $6.4m and its shares are popping
A quarter of us will have arthritis by 2040. These ASX biotechs are trying to help
MGC Pharma to sell MGC Derma business to strategic partner
Kombucha maker Food Revolution gains 17pc after $5m juice launch
Archer is working on disease-detecting graphene ‘biosensors’; shares gain
The former CEO of Sirtex Medical has been charged with insider trading
Zelda is testing cannabis to treat insomnia. (That needs to be tested?)
Got Milk: here are the ASX infant formula stocks making a profit
Canadian pot producer Aurora Cannabis posts surprise profit ahead of US listing
Invion says its ovarian cancer cell killer is now 15x more deadly
Milk formula play Keytone loses chairman two months after ASX debut
Infant formula stock Bioxyne expands Asia footprint with Indonesia acquisition
Elixinol goes big in Japan, takes control of local biz
Immutep shares are flying as Merck and Pfizer agree to test cancer drug
Noxopharm discovers way to inhibit autoimmune ‘master switch’
Acrux poked an $8.7bn bear and now it’s fighting back; shares drop 24pc
The world’s biggest cannabis stock dropped 50pc and local pot stocks are struggling
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
